Lumos Diagnostics provides rapid, cost effective point of care solutions for infectious disease. The company’s innovative FebriDx® test is the first and only rapid test to differentiate a viral from bacterial acute respiratory infection including COVID-19. FebriDx has been shown to be highly accurate in detecting COVID-19 infections and identifying infections missed by RT-PCR. FebriDx can enable effective triage and cohorting so viral negative patients can be rapidly cohorted in non-COVID-19 areas allowing viral positive patients to be immediately isolated whilst awaiting confirmatory testing. FebriDx can benefit Emergency Departments and other healthcare settings overcoming the limitations of lab-based PCR tests reducing risk of transmission and improving clinic workflow.
How many organisations/clients currently utilise the service/solution across the UK?
Medical professionals from the NHS in a variety of Healthcare settings to include Emergency Department, Urgent Care, General Practice, Care Homes and Respiratory Nurses in the Community. FebriDx updated MIB has been included on the NICE COVID-19 website which is reserved for technologies which can help in the Pandemic.
Is there anything you would like to make delegates aware of ahead of the Infection Prevention & Control Conference?
Diagnosing and cohorting COVID-19 patients in the emergency department (ED) remains a challenge because of the long turnaround times of lab SARS CoV-2 PCR testing and the need to repeat tests due to false negative results. Consequently, COVID-19 negative patients are exposed to positive patients leading to spread of infection.
FebriDx® is a 10-minute point-of-care test to differentiate viral from bacterial acute respiratory infections and has been shown to be highly accurate in detecting COVID-19 infections and identifying infections missed by RT-PCR. FebriDx can enable effective triaging, so viral negative patients can be rapidly cohorted in non-COVID-19 areas allowing viral positive patients to be immediately isolated whilst awaiting confirmatory testing. highly accurate to rapidly triage and cohort COVID-19 positive patients from negative patients, reducing risk of transmission and improving clinic workflow.
What do you feel are the key points delegates need to digest when considering a partnership with your organisation?
FebriDx can benefit EDs and other healthcare settings overcoming the limitations of lab-based PCR tests and will have even greater utility in the forthcoming influenza season where the ability to cohort viral positive from viral negative patients and streamline confirmatory testing will be even greater
Do you want to add any other key points?
Rapid triaging with FebriDx can prevent the spread of infection. FebriDx can prevent COVID-19 negative patients being exposed to COVID-19 positive patients caused by the delay in lab PCR testing results. FebriDx can also assist the triage of patients which require confirmatory molecular testing. FebriDx is the ideal Rapid, Front Door Triage Test for the Pandemic.